Skip to main content

Table 2 Medications of patients with type 2 diabetes

From: High visceral fat with low subcutaneous fat accumulation as a determinant of atherosclerosis in patients with type 2 diabetes

VFA (cm2) <100 ≥100 p value*
SFA (cm2) <100 (N = 34) ≥100 (N = 39) <100 (N = 11) ≥100 (N = 34)
OHA (%) 41.2 33.3 54.5 54.7 0.164
Sulfonylureas (%) 25.0 0.0 12.5 22.4 0.055
Biguanides (%) 16.7 15.4 0.0 40.8 0.012
Alpha-GIs (%) 25.0 0.0 12.5 10.2 0.048
TZDs (%) 8.3 0.0 7.7 6.1 0.301
DPP4 inhibitors (%) 25.0 42.3 62.5 34.7 0.245
Glinides (%) 8.3 0.0 0.0 0.0 0.070
GLP-1 agonists (%) 0.0 0.0 0.0 2.0 0.754
Insulin (%) 41.2 38.5 18.2 35.9 0.575
ACEIs (%) 0.0 5.4 0.0 3.2 0.516
ARBs (%) 17.6 24.3 45.5 44.4 0.025
CCBs (%) 11.8 5.4 36.4 30.2 0.007
Beta blockers (%) 5.9 18.9 18.2 14.3 0.424
Alpha blockers (%) 0.0 5.4 0.0 1.6 0.383
Diuretics (%) 5.9 24.3 9.1 11.1 0.110
Statins (%) 11.8 16.2 0.0 34.9 0.007
Fibrates (%) 0.0 0.0 0.0 3.2 0.451
UA-lowering agents 0.0 10.8 9.1 6.3 0.289
Anti-platelets (%) 11.8 0.0 9.1 12.7 0.168
  1. Data are expressed as percentage
  2. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, DPP4 dipeptidyl peptidase-4, GI glycosidase inhibitor, GLP-1 glucagon-like peptide-1, OHA oral hypoglycemic agent, TZD thiazolidinedione, UA uric acid
  3. * Chi square test